Tech Company Financing Transactions
Silverback Therapeutics Funding Round
Silverback Therapeutics, based in Seattle, scored $47.5 million in funding from OrbiMed, Alexandria Venture Investments and Celgene.
Transaction Overview
Company Name
Announced On
9/20/2018
Transaction Type
Venture Equity
Amount
$47,500,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
500 Fairview Ave. N 600
Seattle, WA 98109
USA
Seattle, WA 98109
USA
Phone
Website
Email Address
Overview
Silverback Therapeutics (Nasdaq: SBTX) is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness -- until now.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laura Shawver
Chief Medical Officer
Naomi Hunder
Chief Scientific Officer
Valerie Odegard
Founder
Peter Thompson
Vice President
Sateesh Natarajan
VP - Finance
Russ Hawkinson
VP - General Counsel
Jeffrey Pepe
VP - Operations
Patricia Leith
Browse more venture capital transactions:
Prev: 9/20/2018: Immune-Onc Therapeutics venture capital transaction
Next: 9/20/2018: GitLab venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs